Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA.

Saved in:
Bibliographic Details
Title: Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA.
Authors: Handa T; Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.; Late Development Oncology TA Division, AstraZeneca K.K., Tokyo, Japan., Tanaka A; Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan., Shikano M; Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.; Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan., Wakao R; Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.; Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.
Source: Clinical and translational science [Clin Transl Sci] 2026 Jun; Vol. 19 (6), pp. e70642.
Publication Type: Journal Article; Comparative Study
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1752-8062
DOI:10.1111/cts.70642